Pharmena switches to WSE main board
…funding which the company expects to obtain from the share issue − PLN 12.3m (€2.9m), will be spent on the launch of sales of dietary supplements in Poland and in selected EU countries. PLN 0.5m (€0.1m) will be spent on research into 1-MNA drug animal models in new indications.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)